You are viewing the site in preview mode
Skip to main content
|
Author
|
Year
|
Country
|
Total number of patients
|
Mean age
|
Clinical stage
|
Treatment
|
Number of patients with HPV-18 positive
|
Number of patients with HPV-18 negative
|
Median DFS
|
Median PFS
|
Median OS
|
|---|
|
Yat Ming Lau
|
2015
|
Hong Kong, China
|
236
|
54.4
|
I-III
|
radiotherapy+/−chemotherapy.
|
30
|
185
|
73.2% vs. 78.2%, HR: 1.49, 95% CI = 0.78–2.86
|
NA
|
80% vs. 75.7%, HR: 1.23, 95% CI = 0.66–2.27
|
|
Sun-Hye Yang
|
2014
|
Korea
|
116
|
NA
|
I-IIA
|
surgery
|
15
|
101
|
NA
|
HR: 5.2, 95% CI = 1.29–20.9, P = 0.02
|
Not significant
|
|
Rossana de Arau ́jo Cata ̃o Zampronha
|
2013
|
Brazil
|
86
|
40
|
I
|
Surgery+radiotherapy
|
25
|
51
|
HR: 0.797, 95% CI = 0.175–3.640
|
NA
|
NA
|
|
Robert A. Burger
|
1996
|
USA
|
291
|
NA
|
I-IV
|
radical hysterectomy and pelvic lymphadenectomy
|
58
|
233
|
NA
|
NA
|
HR: 2.59, 95% CI = 1.08–6.22
|
|
Chyong-Huey Lai
|
2007
|
Taiwan, China
|
1067
|
50
|
IA-IIA
|
surgery
|
176
|
891
|
HR: 1.8, 95% CI = 1.8–2.7
| |
HR: 1.7, 95% CI = 1.1–2.6
|
|
Woo Dae Kang
|
2011
|
Korea
|
204
|
49
|
IB-IIA
|
radical hysterectomy followed by adjuvant radiotherapy or primary radiotherapy with concurrent cisplatin-containing chemotherapy
|
28
|
176
|
NA
|
HR: 2.664, 95% CI = 1.437–4.938
|
NA
|
|
Shizhuo Wang
|
2012
|
China
|
24,041
|
NA
|
I-IV
|
NA
|
2082
|
21,959
|
NA
|
NA
|
HR: 1.704, 95% CI = 1.095–2.654
|
- HPV Human papillomavirus, DFS Disease free survival, HR Hazard ratio, CI Confidence interval, NA Not available, DFS Disease free survival, PFS Progression free survival, OS Overall survival
